Jul 14, 2013 by Dave Williamson1 Final Shot for Hyped Alzheimer's DrugEli Lilly announces news around its phase 3 trial for Alzheimer's drug solanezumab.
Jul 7, 2013 by Dave Williamson and Max MacalusoInhaled Insulin: Biotech Triumph or Future Flop?Should investors still hop on MannKind's bandwagon?
Jul 7, 2013 by Dave Williamson and Max MacalusoCan Cutting-Edge Insulin Hold Off Cheap Generics?Will a cheaper generic insulin win versus a superior and new branded product?
Jul 7, 2013 by Dave Williamson and Max MacalusoIs this Diabetes Drug Class Poised for Disruption?Will Eli Lilly's knock off Novo Nordisk as the the best GLP-1 diabetes drug?
Jul 6, 2013 by Dave WilliamsonThe Cause and Effect of Obamacare's Saved BillionsHere's how Obamacare savings for some consumers are impacting managed care stocks.
Jul 5, 2013 by Dave Williamson and Max MacalusoDissecting the World's Biggest Diabetes Drug StockNovo Nordisk has strong sales from its diabetes treatments and an exciting drug pipeline.
Jul 4, 2013 by Dave WilliamsonObamacare Mandate Delay Saves Big BusinessThe large employer mandate has been postponed until 2015, and hospital stocks are punished.
Jul 2, 2013 by Dave WilliamsonFDA Clinical Hold Squeezes InvestorsWhat Achillion's 25% plunge and hepatitis C drug problems mean for investors.
Jul 1, 2013 by Dave WilliamsonWhy the FDA Rejected This New Insomnia DrugMerck's Suvorexant Food & Drug Administration rejection not a deal breaker for the drug.
Jul 1, 2013 by Dave WilliamsonBreaking Down Dendreon's European RecommendationIt looks increasingly likely that cancer vaccine Provenge could get EU approval.
Jun 30, 2013 by Dave WilliamsonCheap Indian Drugs Spur Rare Congressional BipartisanshipCongress and Big Pharma team up to stop India from selling cheap generic drugs to its citizens.
Jun 30, 2013 by Dave WilliamsonA New Breed of Generic Drugs Poised to DisruptThe world's first biosimilar monoclonal antibodies were recommended for approval in Europe.
Jun 29, 2013 by Dave Williamson and Max MacalusoThe Hidden Way to Invest in ObesityThis small cap stock in phase 3 trials may be the best speculative play of the obesity-drug makers.
Jun 29, 2013 by Dave Williamson and Max MacalusoWill This New Obesity Drug Top Expectations or Disappoint?Can Arena overcome high expectations for its obesity drug launch?
Jun 29, 2013 by Dave Williamson and Max MacalusoCan Government Regulations Curb the Obesity Epidemic?Restaurant chains post their calorie information, and New York City tries instituting limits on sugary drinks.
Jun 27, 2013 by Dave WilliamsonAsk a Fool: Time to Buy Abbott Laboratories?Is Abbott Labs a buy today?
Jun 27, 2013 by Dave WilliamsonAsk a Fool: Buy, Sell or Hold Teva?Is Teva too dangerous to buy right now?
Jun 26, 2013 by Dave WilliamsonBright Spots in Obamacare's Medical Device DisasterDespite the doom, gloom, and excise tax burden, bullish investors can still find reasons for optimism.
Jun 25, 2013 by Dave WilliamsonObamacare Medicaid Expansion Stiff-Arm Hurting Insurers?With 19 states opting out of Obamacare's Medicaid expansion, will it dramatically affect insurance stocks?
Jun 24, 2013 by Dave WilliamsonObamacare: The State of State Exchanges100 days before their October debut, we check in on Obamacare's health-care exchanges.
